Latest Work

The Smart Health Benefits Association continues to advance its mission through active advocacy and policy engagement. Our recent work includes preparing and submitting formal letters to government agencies, ensuring that the voice of our members is represented in national discussions on healthcare, workplace benefits, and financial wellness.

Modernizing the Medical Expense Tax Credit (METC)

The Medical Expense Tax Credit (METC) in Canada, a non-refundable tax credit for qualifying medical expenses, can be updated to include preventive health and wellness expenses.

Reconsideration of C-64 Legislative Costing Note Conclusions

On behalf of the Smart Health Benefits Coalition, we are writing to seek reconsideration of the Legislative Costing Note for Bill C-64 issued on May 15, 2024, and which you

Pharmacare Bill Confirmed to Cost Billions More and Eliminate Patient Choice

The current federal pharmacare legislation (Bill C-64) threatens to balloon in cost, disrupt coverage and limit patient choice, and millions of Canadians stand to lose portions of their employer-sponsored drug

HESA Study Submission

The SHBA fully agrees – it is unacceptable that people in our communities across Canada are currently living with little or no coverage for essential medications; having slipped through the

HT Research – Use federal pharmacare funding to fill in coverage gaps

Why would we want to spend money on people that already are successfully having coverage? We believe we could use that money to repurpose that. Why not take that money

Lobby Monitor – Use federal pharmacare funding to fill in coverage gaps

A new voice is on the Hill calling for a mixed-payer pharmacare program. Their message to the feds is that the government should “repurpose” pharmacare funding to help Canadians with

SHBC Statement on Legislation. February 29, 2024

In response to the introduction of legislation today with respect to drug coverage for Canadians, theSmart Health Benefits Coalition issued the following statement:

National Pharmacare Discussion

We support a hybrid model of coverage delivery where the private and public sector each play a role.